16 results about "Neurological pain" patented technology

The present disclosure provides methods of treating multiple sclerosis associated spasticity or neurological pain in a patient with renal impairment by administering cannabinoids oromucosal spray.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

Methods, systems and devices are provided to stimulate the vestibular system in such a way as to alleviate post-infection symptoms of COVID-19. A device with one or more electrodes placed over a subject's scalp provides vestibular nerve stimulation (VeNS) to the vestibular nerve, which is then carried into the vestibular nucleus in the brainstem to alleviate post-infection symptoms of COVID-19 related to the vestibular system, including dizziness, fatigue, malaise, headache, nerve pain, insomnia and sleep problems, anxiety, depression and difficulty concentrating. The characteristics of the stimulation signal and duration of the treatment are configured to allow the treatment to be delivered at the onset of one or more symptoms or at regular daily intervals alleviate the post-infection symptoms immediately or over a longer period of time.

The present application relates to S ) -2-((3-((benzo[ d [1,3]dioxolane-5-oxomethyl)benzyl)-amino)propanamide, to pharmaceutical compositions containing it, and to the use of this crystalline form for the preparation of a medicament for the prevention and / or treatment of pain (e.g. neuropathic pain, including chronic neuropathic pain or neuropathological pain).

The utility model discloses a neurology pain relieving device which comprises a relieving device body, the upper surface of the relieving device body is fixedly connected with a limiting inserting rod, the surface of the outer ring of the limiting inserting rod is sleeved with a base assembly in a limiting mode, and a telescopic rod is installed on the upper surface of the base assembly. A backrest assembly is installed on the upper surface of the telescopic rod, and a cushioning cushion is clamped to the upper surface of the base assembly in a limiting mode. According to the device, when a user needs to relieve, the user needs to sit on the cushioning cushion, then the back of the user leans against the massage assembly and the cushioning backrest, and then the head of the user leans against the head backrest assembly and the heating structure assembly, so that the user can perform massage and hot compress on the human body; nervous muscles and nerves of the human body can be relaxed through massage, blood circulation of the human body can be promoted and pains can be relieved through hot compress, and therefore a user can efficiently use and relieve the pains of the neurology department.

To provide a composition suitable for topical delivery of cannabidiol to improve availability of cannabidiol at a local administration site of a mammal in a therapeutically effective amount necessary to reduce or alleviate local symptoms of psoriasis or arthritis, such as rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and / or psoriatic arthritis.SOLUTION: A hydroalcoholic gel composition is disclosed for alleviating symptoms of psoriasis or arthritis, such as pain resulting from arthritic diseases and / or psoriatic arthritis, and / or neurological pain, such as pain resulting from sclerosis, e.g., multiple sclerosis, in a subject. Such a composition may comprise, inter alia, 0.1-20% cannabidiol, a skin penetration enhancer, ethanol, and one or more thickeners and / or gelling agents.SELECTED DRAWING: None

The invention belongs to the technical field of medicine, and particularly relates to application of LXH-2103 in preparation of medicine for treating pain and medicine dependence and a medicine composition of the LXH-2103. According to the application of the LXH-2103 disclosed by the invention in pain, the pain is acute incision pain, osteoarthritis pain, sciatica and cancer pain. The intravenous injection dosage of the medicine in an acute incision pain model animal is 7.5-20 mg / kg, and the oral administration dosage of the medicine in gavage is 20 mg / kg. The injection dosage of the medicine for treating osteoarthritis pain and sciatica is 2.5-7.5 mg / kg, and the oral administration dosage of the medicine for gavage is 20 mg / kg. The injection dosage of the medicine for cancer pain is 3-12 mg / kg, and the oral administration dosage of the medicine for gavage is 30 mg / kg. According to the establishment of the LXH-2103 in the pain model and the application of the LXH-2103 in the pain, a plurality of pain animal models are established, and the application of the LXH-2103 in the pain treatment is evaluated.

A hydroalcoholic gel composition formulated for topical use is disclosed for alleviating symptoms of psoriasis or arthritis, such as pain resulting from arthritic diseases and / or psoriatric arthritis and / or neurological pain, such as pain resulting from sclerosis, e.g. multiple sclerosis in mammals. Such composition may comprise, inter alia, 0.1-20 % cannabidiol, a skin penetration enhancer, ethanol, and present in an amount of 0.4-2 % (by weight), one or more thickeners or gelling agents, and water in a quantity for the composition to a total of 100 % (by weight).

Disclosed here are compositions including exosomes loaded with therapeutic agents, for example one or more anesthetic agents. The composition may be used to treated nerve pain, including peripheral nerve pain.

This invention discloses a reactive oxygen species (ROS) responsive glycyrrhizic acid anti-inflammatory hydrogel and its application in the preparation of drugs for treating compressive neuropathic pain. Belonging to the field of biomedical materials technology, the hydrogel uses glycyrrhizic acid and 1,4-phenylboronic acid as raw materials. It is heated in an alkaline environment until a homogeneous mixed solution is formed, and then naturally cooled to room temperature to obtain the ROS responsive glycyrrhizic acid anti-inflammatory hydrogel. This hydrogel possesses good injectability, self-healing properties, biocompatibility, and biodegradability. It can specifically cleave borate ester bonds in the highly reactive oxygen species pathological microenvironment of diabetic patients with lumbar disc herniation, releasing glycyrrhizic acid on demand. By targeting and regulating the PI3K-AKT signaling pathway, it promotes the polarization of macrophages from a pro-inflammatory M1 phenotype to a reparative M2 phenotype, significantly inhibiting the inflammatory response of the dorsal root ganglion and the dorsal horn of the spinal cord, effectively relieving compressive neuropathic pain in the dorsal root ganglion caused by diabetic patients with lumbar disc herniation, and has good prospects for clinical translation.

The invention particularly discloses a pharmaceutical composition for treating diabetic neuralgia and application of the pharmaceutical composition, and relates to the technical field of biological medicines. The invention provides a pharmaceutical composition for treating neuralgia, the pharmaceutical composition comprises infliximab and lipoic acid, and the pharmaceutical composition blocks a TNF-alpha pathway and synergistically resists oxidative stress, so that neuroinflammation and pain are relieved fundamentally, the defects of central side effects and insufficient curative effects of existing drugs are overcome, and a new treatment choice is provided for patients with diabetic neuralgia.

A hydroalcoholic gel composition formulated for topical use is disclosed for alleviating symptoms of psoriasis or arthritis, such as pain resulting from arthritic diseases and / or psoriatric arthritis and / or neurological pain, such as pain resulting from sclerosis, e.g. multiple sclerosis in mammals. Such composition may comprise, inter alia, 0.1-20 % cannabidiol, a skin penetration enhancer, ethanol, and present in an amount of 0.4-2 % (by weight), one or more thickeners or gelling agents, and water in a quantity for the composition to a total of 100 % (by weight).

The application discloses a biological adhesive tape for a nerve stump after amputation and a preparation method thereof. The biological adhesive tape comprises an outer layer and an inner layer, and the outer layer and the inner layer are connected by a PEG-based adhesive layer. The outer surface of the outer layer is coated with a PDMS hydrophobic coating layer. The inner surface of the inner layer is also coated with a PEG-based adhesive layer. The outer layer is made of recombinant human collagen type I and contains dexamethasone drug-loaded microspheres. The inner layer is made of recombinant human collagen type I and contains gabapentin drug-loaded microspheres. The outer layer of the biological adhesive tape can inhibit inflammatory response and reduce foreign body reaction by releasing glucocorticoids. The inner layer can prevent and relieve neuropathic pain by releasing gabapentin. The physical adhesion of the adhesive tape can prevent the growth of nerve fibers outward, thereby reducing the risk of neuroma formation. The biological adhesive tape has high flexibility in application, is suitable for nerve stumps with different diameters and shapes, and is suitable for complex trauma.

The application discloses a wearable pain relief device and a remote monitoring system thereof, which comprises a multi-modal physiological sensor array, a data fusion processing module, a control module, a transcutaneous electrical stimulation output module, a communication module and a remote monitoring system. The multi-modal sensor array collects pain-related physiological parameters such as electromyography, skin conductance, body surface temperature, heart rate and brain oxygen, the data fusion module generates a pain estimate value, the control module dynamically adjusts the stimulation intensity based on the PID+derivative compensation algorithm, and the transcutaneous electrical stimulation module outputs an electric current to intervene in pain. The communication module uploads data to the remote monitoring system, and medical staff can monitor and remotely adjust parameters in real time through the cloud platform. The application realizes real-time monitoring, intelligent control and remote intervention of pain, has the advantages of personalized treatment, data security and scalability, and is suitable for postoperative pain management, chronic neuropathic pain and the like.

The invention belongs to the technical field of diagnostic markers, and particularly relates to a tyrosine-containing marker and application thereof in diagnosis of diabetic peripheral neuralgia. The invention provides a new approach for diagnosing, evaluating, preventing and treating diabetic peripheral neuralgia based on tyrosine, and the tyrosine is found to be abnormally reduced in a DPNP patient and a related animal model and is closely related to occurrence and development of the peripheral neuralgia. Therefore, a new biomarker and a potential intervention means are provided for early recognition, risk assessment and targeted intervention of DPNP.